인간 마이크로바이옴 시장 : 업계 동향과 세계 예측 - 제품 유형별, 분자 유형별, 표적 적응증별, 치료 영역별, 투여 경로별, 주요 지역별

HUMAN MICROBIOME MARKET: OVERVIEW

As per Roots Analysis, the global human microbiome market is estimated to grow from USD 791 million in the current year to USD 6,091 million by 2035, at a CAGR of 20.4% during the forecast period, till 2035.

The market sizing and opportunity analysis has been segmented across the following parameters:

Type of Product

• Probiotic Drugs
• Other Drugs

Type of Molecule

• Small Molecules
• Biologics

Target Indication

• Colorectal Cancer
• Diabetes Mellitus
• Inflammatory Bowel Disease
• Irritable Bowel Syndrome
• Graft vs. Host Disease
• Necrotizing Enterocolitis
• Primary Hyperoxaluria
• Recurrent CDI

Therapeutic Area

• Digestive and Gastrointestinal Disorders
• Infectious Diseases
• Metabolic Disorders
• Oncological Disorders
• Rare Disorders

Route of Administration

• Oral
• Rectal

Key Geographical Regions

• North America
• Europe
• Asia-Pacific
• Rest of the World

HUMAN MICROBIOME MARKET: GROWTH AND TRENDS

The term microorganism were previously associated with harmful disease-causing agents, until the discovery of certain beneficial microbial colonies in the human system. Humans and a variety of microbial species of bacteria, yeast and protozoa, are known to co-exist in mutually beneficial relationships. Moreover, it is estimated that the human gut microbiome consists of about 100 trillion microorganisms. Notably, this figure significantly outnumbers the total number of cells in the human body.

The majority of microorganisms provide significant benefits to humans by conferring traits and capabilities that would otherwise be absent. The healthy variety of bacteria in the gut has significant potential to enhance immunity and offer a wide range of health benefits. This has led to extensive research and development efforts by human microbiome based live biotherapeutics / diagnostic developers to make significant strides, in terms of progressing proprietary product candidates into the clinic. In addition, owing to the strong association between the human microbiome and health, a myriad of therapeutic interventions based on manipulation of commensal microbes are under development.

HUMAN MICROBIOME MARKET: KEY INSIGHTS

The report delves into the current state of the human microbiome market and identifies potential growth opportunities within industry. Some key findings from the report include:

• Presently, over 70 companies, worldwide, have taken initiatives to develop therapies that can manipulate the human microbiome; the market is characterized by the presence of small companies.
• The pipeline features 230+ human microbiome therapeutics that are currently being evaluated across different phases of development; the majority of these are designed for oral delivery.
• Nearly 30% of the pipeline drugs are in clinical phase of development, while more than 150 drugs are in preclinical and discovery stages. Clinical stage drugs are primarily being developed for infectious diseases and digestive disorders, while candidates in preclinical and discovery stages are focused on oncological disorders.
• Currently, over 40 companies, worldwide, are engaged in providing various diagnostics and screening / profiling test kits for the purpose of disease detection and analysis of human microflora composition and function.
• More than 75 diagnostics and screening / profiling test are available / under development.

Of these, around 80% of the tests are available in the market, while rest are under development.

• Over 70 microbiome focused diagnostic and screening / profiling tests are available in the market; such test kits allow testing of different sample types across various therapeutic areas.

• Presently, FMTs are the only commercially available microbiome product; in fact, more than 400 clinical trials evaluating FMTs, sponsored by non-industry players, have been registered in the past decade.
• Several well-funded start-ups have entered this domain; our proprietary start-up health indexing analysis confirms the presence of a number of players that offer significant promise in developing microbiome therapeutics.
• The rising interest is also reflected in the wide array of partnerships being established between various stakeholders in the recent past; research agreements emerged as the most popular type of partnership model.
• Partnership activity in this domain increased at a CAGR of 26%, since 2017. It is worth highlighting that majority of the deals were R&D agreements, representing over 35% of the total number of partnerships signed in the given time period.
• Numerous investors, having realized the benefits and future opportunities of microbiome therapeutics in the treatment of various disorders, have invested more than USD 1 billion in start-ups, since 2019.
• Of the total amount invested, over USD 563 million was raised through venture capital financing, representing over 56% of the overall funding activity in this domain. Further, 36 instances of grants / awards were also reported, wherein players collectively raised more than USD 137 million.
• More than 25 industry players claim to be engaged in the manufacturing of microbiome-based biologics for various therapeutic purposes; majority of these firms are headquartered in Europe.
• Driven by ongoing research and advancements, the human microbiome therapeutics and diagnostics market is anticipated to grow at a significant pace in the coming years.
• Specifically, the human microbiome therapeutics market is anticipated to grow at a CAGR of 20.4%; the opportunity is likely to be well-distributed across different products, therapeutic areas and geographies.

• In the coming decade, we anticipate the opportunity for microbiome diagnostics market to grow at an annualized rate of ~53% across different supply channels.
• As late-stage therapeutics will get approved by the FDA in the foreseen future, microbiome therapeutics are anticipated to capture more than 60% share of total microbiome market by 2035.

Example Players in the Human Microbiome Market

• 4D Pharma
• Biosotia Microbiomics
• DNA Genotek
• Finch Therapeutics
• GoodGut
• Infant Bacterial Therapeutics
• Invivo Healthcare
• MaaT Pharma
• OxThera
• Qu Biologics
• Rebiotix
• Seres Therapeutics
• Servatus
• Shoreline Biome

HUMAN MICROBIOME MARKET: RESEARCH COVERAGE

• Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the global human microbiome market, focusing on key market segments, including [A] type of product, [B] type of molecule, [C] target indication, [D] therapeutic area, [E] route of administration and [F] key geographical regions.
• Microbiome Therapeutics Market Landscape: A comprehensive evaluation of microbiome therapeutics, based on several relevant parameters, such as [A] phase of development of product candidates, [B] type of molecule, [C] type of therapy, [D] target indication(s), [E] therapeutic area(s), [F] route of administration, [G] type of drug formulation, [H] type of microbiome therapy, [I] combination drug, [J] dosing frequency and [K] special drug designations (if any). Additionally, a comprehensive evaluation of the microbiome companies engaged in the development of microbiome therapeutics, based on several relevant parameters, such as [A] year of establishment, [B] company size and [C] location of headquarters.
• Microbiome Therapeutics Company and Drug Profiles: In-depth profiles of key players that are currently engaged in the development of microbiome therapeutics, focusing on [A] overview of the company, [B] financial information (if available) [C] microbiome-based drug portfolio, [D] information on clinical trial and [E] recent developments and an informed future outlook. Additionally, in-depth profiles of key players that are currently engaged in more than six therapeutic programs, focusing on [A] overview of the company, [B] financial information (if available), [C] drug portfolio and [D] informed future outlook.
• Microbiome Diagnostics and Screening / Profiling Tests Market Landscape: A comprehensive evaluation of various types of microbiome diagnostic and screening / profiling tests, based on several relevant parameters, such as [A] stage of development, [B] type of sample analyzed, [C] type of screening technique. [D] target indication(s), [E] key therapeutic area(s) and [F] purpose of diagnosis. Additionally, a comprehensive evaluation of diagnostics and screening / profiling test providers(s), based on several relevant parameters, such as [A] year of establishment, [B] company size and [C] location of headquarters.
• Microbiome Diagnostics and Screening / Profiling Tests Providers Company Profiles: In-depth profiles of key players that are currently engaged in the development of microbiome diagnostics and screening / profiling tests, focusing on [A] overview of the company, [B] financial information (if available) [C] diagnostic or screening / profiling test portfolio and [D] recent developments and an informed future outlook.
• Clinical Trial Analysis: An insightful analysis of clinical trials related to fecal transplant, based on several parameters, such as [A] trial status, [B] trial registration year, [C] trial phase, [D] year-wise trend of completed and recruiting trials, [E] study design, [F] number of patients enrolled, [G] age category of the patients enrolled, [H] type of sponsor / collaborator, [I] active industry and non-industry players, and [J] location of the trials. Furthermore, an insightful analysis of various stool banks based on [A] year of establishment and [B] location of headquarters, along with brief profiles of the most prominent stool banks located across the globe.
• Attractiveness Competitiveness (AC) Matrix: A comprehensive business portfolio analysis based on an attractiveness and competitiveness (AC) framework, featuring the current market attractiveness and competition across the most popular disease indication(s) for which microbiome therapeutics are under investigation.
• Start-Up Health Indexing: An assessment of the start-ups / small-sized players that are engaged in the development of microbiome therapeutics and diagnostics, based on relevant parameters, such as [A] number of microbiome therapeutics under development, [B] diversity of product portfolio, [C] funding amount, [D] partnership activity and [E] disease indication(s) being treated.
• Key Therapeutic Areas: In-depth analysis of the most commonly targeted therapeutic indications and information on microbiome-based drugs that are being developed against them, based on [A] key epidemiological facts about specific diseases, [B] available methods of diagnosis and [C] currently available treatment options and their side effects.
• Partnerships and Collaborations: An insightful analysis of the deals inked by stakeholders in the human microbiome market, based on several parameters, such as [A] year of partnership, [B] type of partnership, [C] type of product, [D] target indication, [E] therapeutic area, [F] type of company, [G] type of partner, [H] most active players and [I] geographical distribution of the partnership activity.
• Funding and Investments: An in-depth analysis of the fundings raised by human microbiome companies, based on relevant parameters, such as [A] year of investment, [B] amount invested, [C] type of funding, [D] type of company, [E] purpose of funding, [F] type of product, [G] target indication, [H] therapeutic area, [I] geographical analysis, [J] most active players and [K] most active investors.
• Case Study: A detailed discussion on the various steps involved in the development and manufacturing of microbiome therapeutics, along with information of contract manufacturers, focusing on [A] year of establishment, [B] location of headquarters, [C] company size, [D] scale of operation, [E] type of product manufactured and [F] type of formulation. Additionally, a detailed discussion on the key considerations that are required for selecting a CMO / CRO partner.
• Big Data and Microbiome Therapeutics: A comprehensive assessment of the emerging role of big data, representing efforts made to develop and implement various algorithms / tools to analyze data generated from microbiome research. Further, a detailed google trends analysis demonstrating a rising interest in stakeholders to use big data tools for supporting microbiome research over the past decade.

KEY QUESTIONS ANSWERED IN THIS REPORT

• How many companies are currently engaged in this market?
• Which are the leading companies in this market?
• What factors are likely to influence the evolution of this market?
• What is the current and future market size?
• What is the CAGR of this market?
• How is the current and future market opportunity likely to be distributed across key market segments?

REASONS TO BUY THIS REPORT

• The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
• Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
• The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.

ADDITIONAL BENEFITS

• Complimentary PPT Insights Packs
• Complimentary Excel Data Packs for all Analytical Modules in the Report
• 15% Free Content Customization
• Detailed Report Walkthrough Session with Research Team
• Free Updated report if the report is 6-12 months old or older

TABLE OF CONTENTS

1. PREFACE

• 1.1. Scope of the Report
• 1.2. Research Methodology
  • 1.2.1. Research Assumptions
  • 1.2.2. Project Methodology
  • 1.2.3. Forecast Methodology
  • 1.2.4. Robust Quality Control
  • 1.2.5. Key Considerations
    • 1.2.5.1. Demographics
    • 1.2.5.2. Economic Factors
    • 1.2.5.3. Government Regulations
    • 1.2.5.4. Supply Chain
    • 1.2.5.5. COVID Impact / Related Factors
    • 1.2.5.6. Market Access
    • 1.2.5.7. Healthcare Policies
    • 1.2.5.8. Industry Consolidation
• 1.3 Key Questions Answered
• 1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

• 3.1. Chapter Overview
• 3.2. Concept of Microbiota and Microbiome
  • 3.2.1. Discovery of the Human Microbiome
  • 3.2.2. Functions of the Human Microbiome
• 3.3. Overview of Gut Flora
  • 3.3.1. Role of Gut Flora in Human Health
  • 3.3.2. Factors Affecting Gut Flora
    • 3.3.2.1. Antibiotic Consumption
    • 3.3.2.2. Age and Pregnancy
      • 3.3.2.2.1. Mode of Childbirth
      • 3.3.2.2.2. Type of Feeding
      • 3.3.2.2.3. Antibiotic Consumption by Mother
    • 3.3.2.3. Stress-related Factors
    • 3.3.2.4. Dietary Factors
    • 3.3.2.5. Impact of Lifestyle
• 3.4. Microbiome and Associated Diseases
  • 3.4.1. Cancer
  • 3.4.2. Inflammatory Bowel Disease (IBD)
  • 3.4.3. Obesity
  • 3.4.4. Parkinson's Disease
  • 3.4.5. Type 2 Diabetes
  • 3.4.6. Other Disease Indications
• 3.5. Impact of Microbiota on Drug Pharmacokinetics
• 3.6. Impact of Microbiota on Therapeutic Outcomes
• 3.7. Microbiome Therapeutics
  • 3.7.1. Probiotics
    • 3.7.1.1. Beneficial Bacterial Strains
      • 3.7.1.1.1. Lactobacilli
      • 3.7.1.1.2. Bifidobacteria
      • 3.7.1.1.3. Others
    • 3.7.1.2. Key Therapeutic Areas
      • 3.7.1.2.1. Antibiotic-Associated Diarrhea (AAD)
      • 3.7.1.2.2. Bacterial Vaginosis
      • 3.7.1.2.3. High Blood Pressure
      • 3.7.1.2.4. Hypercholesterolemia
      • 3.7.1.2.5. Infectious Childhood Diarrhea (ICD)
      • 3.7.1.2.6. Inflammatory Bowel Disease (IBD)
      • 3.7.1.2.7. Lactose Intolerance
      • 3.7.1.2.8. Vitamin Production
      • 3.7.1.2.9. Weight Management
    • 3.7.1.3. Side Effects of Probiotics
  • 3.7.2. Prebiotics
    • 3.7.2.1. Sources of Prebiotics
    • 3.7.2.2. Types of Prebiotics
      • 3.7.2.2.1. Fructo-Oligosaccharides (FOS)
      • 3.7.2.2.2. Galacto-Oligosaccharides (GOS)
      • 3.7.2.2.3. Inulin
    • 3.7.2.3. Key Therapeutic Areas
      • 3.7.2.3.1. Antibiotic Associated Diarrhea (AAD)
      • 3.7.2.3.2. Constipation
      • 3.7.2.3.3. Gastrointestinal Diseases
      • 3.7.2.3.4. Dysbiosis
    • 3.7.2.4. Side Effects of Prebiotics
• 3.8. The Human Microbiome Project (HMP)
  • 3.8.1. Project Approach
  • 3.8.2. Project Initiatives
  • 3.8.3. Project Achievements
• 3.9. Regulatory Guidelines for Live Biotherapeutic Products (LBPs)
• 3.10. Key Challenges Associated with the Development of Microbiome Therapeutics
• 3.11. Future Perspectives

4. MICROBIOME THERAPEUTICS: MARKET LANDSCAPE

• 4.1. Chapter Overview
• 4.2. Microbiome Therapeutics: Clinical Pipeline
  • 4.2.1. Analysis by Phase of Development
  • 4.2.2. Analysis by Type of Molecule
  • 4.2.3. Analysis by Phase of Development and Type of Molecule
  • 4.2.4. Analysis by Type of Biologic
  • 4.2.5. Analysis by Type of Product
  • 4.2.6. Analysis by Target Indication
  • 4.2.7. Analysis by Therapeutic Area
  • 4.2.8. Analysis by Route of Administration
  • 4.2.9. Analysis by Type of Formulation
  • 4.2.10. Analysis by Dose Frequency
  • 4.2.11. Analysis by Type of Therapy
  • 4.2.12. Analysis by Combination Drug
• 4.3. Microbiome Therapeutics: Preclinical Pipeline
  • 4.3.1. Analysis by Phase of Development
  • 4.3.2. Analysis by Type of Molecule
  • 4.3.3. Analysis by Phase of Development and Type of Molecule
  • 4.3.4. Analysis by Type of Biologic
  • 4.3.5. Analysis by Type of Product
  • 4.3.6. Analysis by Target Indication
  • 4.3.7. Analysis by Therapeutic Area
  • 4.3.8. Analysis by Route of Administration
• 4.4. Microbiome Therapeutics: List of Drug Developers
  • 4.4.1. Analysis by Year of Establishment
  • 4.4.2. Analysis by Company Size
  • 4.4.3. Analysis by Location of Headquarters
  • 4.4.4. Analysis by Company Size and Location of Headquarters

5. MICROBIOME THERAPEUTICS: COMPANY AND DRUG PROFILES

• 5.1. Chapter Overview
• 5.2. Microbiome Therapeutics Developers: Companies with Candidate(s) in Highest Phase of Development
• 5.3. Finch Therapeutics
  • 5.3.1. Company Overview
  • 5.3.2. Microbiome-Based Product Portfolio
    • 5.3.2.1. CP101
      • 5.3.2.1.1. Drug Overview
      • 5.3.2.1.2. Current Status of Development
      • 5.3.2.1.3. Clinical Studies
  • 5.3.3. Recent Developments and Future Outlook
• 5.4. Infant Bacterial Therapeutics
  • 5.4.1. Company Overview
  • 5.4.2. Microbiome-Based Product Portfolio
    • 5.4.2.1. IBP-9414
      • 5.4.2.1.1. Drug Overview
      • 5.4.2.1.2. Current Status of Development
      • 5.4.2.1.3. Clinical Studies
  • 5.4.3. Recent Developments and Future Outlook
• 5.5. MaaT Pharma
  • 5.5.1. Company Overview
  • 5.5.2. Microbiome-Based Product Portfolio
    • 5.5.2.1. MaaT013
      • 5.5.2.1.1. Drug Overview
      • 5.5.2.1.2. Current Status of Development
      • 5.5.2.1.3. Clinical Studies
  • 5.5.3. Recent Developments and Future Outlook
• 5.6. OxThera
  • 5.6.1. Company Overview
  • 5.6.2. Microbiome-Based Product Portfolio
    • 5.6.2.1. Oxabact
      • 5.6.2.1.1. Drug Overview
      • 5.6.2.1.2. Current Status of Development
      • 5.6.2.1.3. Clinical Studies
  • 5.6.3. Recent Developments and Future Outlook
• 5.7. Rebiotix (acquired by Ferring Pharmaceuticals)
  • 5.7.1. Company Overview
  • 5.7.2. Financial Information
  • 5.7.3. Microbiome-Based Product Portfolio
    • 5.7.3.1. RBX2660
      • 5.7.3.1.1. Drug Overview
      • 5.7.3.1.2. Current Status of Development
      • 5.7.3.1.3. Clinical Studies
  • 5.7.4. Recent Developments and Future Outlook
• 5.8. Seres Therapeutics
  • 5.8.1. Company Overview
  • 5.8.2. Financial Information
  • 5.8.3. Microbiome-Based Product Portfolio
    • 5.8.3.1. SER-109
      • 5.8.3.1.1. Drug Overview
      • 5.8.3.1.2. Current Status of Development
      • 5.8.3.1.3. Clinical Studies
      • 5.8.3.1.4. Clinical Trial End-Point Analysis
• 5.9. Microbiome Therapeutics Developers: Companies with Maximum Number of Therapeutic Programs
• 5.10. 4D Pharma
  • 5.10.1. Company Overview
  • 5.10.2. Financial Information
  • 5.10.3. Microbiome-based Drug Portfolio
  • 5.10.4. Recent Developments and Future Outlook
• 5.11. Biosortia Pharmaceuticals
  • 5.11.1. Company Overview
  • 5.11.2. Microbiome-based Drug Portfolio
  • 5.11.3. Recent Developments and Future Outlook
• 5.12. Qu Biologics
  • 5.12.1. Company Overview
  • 5.12.2. Microbiome-based Drug Portfolio
  • 5.12.3. Recent Developments and Future Outlook
• 5.13. Servatus
  • 5.13.1. Company Overview
  • 5.13.2. Microbiome-based Drug Portfolio
  • 5.13.3. Recent Developments and Future Outlook

6. CLINICAL TRIAL ANALYSIS: HUMAN MICROBIOME THERAPEUTICS

• 6.1. Chapter Overview
• 6.2. Human Microbiome Therapeutics: List of Clinical Trials
  • 6.2.1. Analysis by Trial Status
  • 6.2.2. Analysis by Trial Registration Year
  • 6.2.3. Analysis by Trial Registration Year and Type of Study
  • 6.2.4. Analysis by Trial Phase and Trial Status
  • 6.2.5. Year-wise Trend of Completed and Recruiting Trials
  • 6.2.6. Analysis by Study Design
  • 6.2.7. Analysis by Patient Enrollment
  • 6.2.8. Analysis by Age Category
  • 6.2.9. Analysis by Type of Sponsor / Collaborator
  • 6.2.10. Most Active Industry Players: Analysis by Number of Registered Trials
  • 6.2.11. Most Active Non-Industry Players: Analysis by Number of Registered Trials
  • 6.2.12. Analysis by Trial Location
  • 6.2.13. Analysis by Trial Status and Geography

7. MICROBIOME DIAGNOSTICS AND SCREENING / PROFILING TESTS: MARKET LANDSCAPE

• 7.1. Chapter Overview
• 7.2. Overview of Microbiome Diagnostics and Screening / Profiling Tests
• 7.3. Microbiome Diagnostics and Screening / Profiling Tests: Marketed and Under Development Products
  • 7.3.1. Analysis by Stage of Development
  • 7.3.2. Analysis by Type of Test
  • 7.3.3. Analysis by Stage of Development and Type of Test
  • 7.3.4. Analysis by Type of Sample Analyzed
  • 7.3.5. Analysis by Type of Screening Technique
  • 7.3.6. Analysis by Target Indication
  • 7.3.7. Analysis by Therapeutic Area
  • 7.3.8. Analysis by Purpose of Test
• 7.4. Microbiome Diagnostic and Screening / Profiling Tests Providers
  • 7.4.1. Analysis by Year of Establishment
  • 7.4.2. Analysis by Company Size
  • 7.4.3. Analysis by Location of Headquarters
  • 7.4.4. Analysis by Company Size and Location of Headquarters

8. MICROBIOME DIAGNOSTIC AND SCREENING / PROFILING TEST PROVIDERS: COMPANY PROFILES

• 8.1. Chapter Overview
• 8.2. Shoreline Biome
  • 8.2.1. Company Overview
  • 8.2.2. Microbiome Test Portfolio
  • 8.2.3. Recent Developments and Future Outlook
• 8.3. DNA Genotek
  • 8.3.1. Company Overview
  • 8.3.2. Microbiome Test Portfolio
  • 8.3.3. Recent Developments and Future Outlook
• 8.4. Invivo Healthcare
  • 8.4.1. Company Overview
  • 8.4.2. Microbiome Test Portfolio
  • 8.4.3. Recent Developments and Future Outlook
• 8.5. GoodGut
  • 8.5.1. Company Overview
  • 8.5.2. Microbiome Test Portfolio
  • 8.5.3. Recent Developments and Future Outlook
• 8.6. BiomeDx
  • 8.6.1. Company Overview
  • 8.6.2. Microbiome Test Portfolio
  • 8.6.3. Recent Developments and Future Outlook

9. FECAL MICROBIOTA THERAPY (FMT)

• 9.1. Chapter Overview
• 9.2. Introduction to Fecal Microbiota Therapies (FMT)
• 9.3. Historical Overview
• 9.4. Fecal Microbiota Therapies: Procedure and Clinical Relevance
  • 9.4.1. Donor Selection
  • 9.4.2. Administration Procedure
  • 9.4.3. Routes of Administration
  • 9.4.4. Consequences and Adverse Events
  • 9.4.5. Clinical Guidelines Associated with FMT
• 9.5. Regulatory Guidelines Related to Fecal Microbiota Therapies
• 9.6. Insurance Coverage for Fecal Microbiota Therapies
• 9.7. Fecal Microbiota Therapies: Marketed and Development Pipeline
  • 9.7.1. Analysis by Application Area
  • 9.7.2. Analysis by Status of Development
  • 9.7.3. Analysis by Target Indication
  • 9.7.4. Analysis by Therapeutic Area
  • 9.7.5. Analysis by Route of Administration
  • 9.7.6. Fecal Microbiota Therapies: List of Developers
    • 9.7.6.1. Analysis by Year of Establishment
    • 9.7.6.2. Analysis by Company Size
    • 9.7.6.3. Analysis by Location of Headquarters

10. CLINICAL TRIALS ANALYSIS: FECAL MICROBIOTA THERAPY

• 10.1. Chapter Overview
• 10.2. Scope and Methodology
• 10.3. Fecal Microbiota Therapies: Clinical Trial Analysis
  • 10.3.1. Analysis by Trial Status
  • 10.3.2. Analysis by Trial Registration Year
  • 10.3.3. Analysis by Trial Recruitment Status
  • 10.3.4. Analysis by Trial Phase and Number of Patients Enrolled
  • 10.3.5. Analysis by Study Design
  • 10.3.6. Leading Industry Players: Analysis by Number of Registered Trials
  • 10.3.7. Leading Non-industry Players: Analysis by Number of Registered Trials
  • 10.3.8. Analysis by Trial Location
  • 10.3.9. Analysis by Trial Status and Geography

11. ATTRACTIVENESS COMPETITIVENESS (AC) MATRIX

• 11.1. Chapter Overview
• 11.2. AC Matrix: An Overview
  • 11.2.1. Strong Business Units
  • 11.2.2. Average Business Units
  • 11.2.3. Weak Business Units
• 11.3. AC Matrix: Analytical Methodology
• 11.4. AC Matrix: Plotting the Information
• 11.5. AC Matrix: Analyzing the Data
  • 11.5.1. Strong Business Units
  • 11.5.2. Average Business Units
  • 11.5.3. Weak Business Units
• 11.6. Concluding Remarks

12. MICROBIOME RELATED INITIATIVES OF BIG PHARMA PLAYERS

• 12.1. Chapter Overview
• 12.2. Scope and Methodology
• 12.3. Initiatives of Big Pharma Players
  • 12.3.1. Analysis by Portfolio Diversity
  • 12.3.2. Analysis by Phase of Development
  • 12.3.3. Analysis by Type of Molecule
  • 12.3.4. Analysis by Type of Therapy
  • 12.3.5. Analysis by Diversity of Therapeutic Areas
• 12.4. Benchmarking Analysis of Big Pharma Players
  • 12.4.1. Spider Web Analysis: Company A
  • 12.4.2. Spider Web Analysis: Company B
  • 12.4.3. Spider Web Analysis: Company C
  • 12.4.4. Spider Web Analysis: Company D
  • 12.4.5. Spider Web Analysis: Company E
  • 12.4.6. Spider Web Analysis: Company F
  • 12.4.7. Spider Web Analysis: Company G
  • 12.4.8. Spider Web Analysis: Company H
  • 12.4.9. Spider Web Analysis: Company I
  • 12.4.10. Spider Web Analysis: Company J
  • 12.4.11. Spider Web Analysis: Company K

13. START-UP HEALTH INDEXING

• 13.1. Chapter Overview
• 13.2. Scope and Methodology
• 13.3. Benchmarking of Start-ups
  • 13.3.1. Analysis by Portfolio Diversity
  • 13.3.2. Analysis by Phase of Development
  • 13.3.3. Analysis by Diversity in Indication
  • 13.3.4. Analysis by Funding Amount
  • 13.3.5. Analysis by Partnership Activity
  • 13.3.6. Start-up Health Indexing: Roots Analysis Perspective
  • 13.3.7. Start-up Health Indexing: Top Five Start-ups

14. KEY THERAPEUTIC AREAS

• 14.1. Chapter Overview
• 14.2. Metabolic Disorders
  • 14.2.1. Diabetes
    • 14.2.1.1. Disease Description
    • 14.2.1.2. Associated Health Risks / Complications
    • 14.2.1.3. Epidemiology
    • 14.2.1.4. Disease Diagnosis
    • 14.2.1.5. Current Treatment Options
      • 14.2.1.5.1. Insulin Therapies
      • 14.2.1.5.2. Non-Insulin Therapies
    • 14.2.1.6. Side Effects of Current Treatment Options
    • 14.2.1.7. Microbiome Therapeutics for Diabetes
  • 14.2.2. Lactose Intolerance
    • 14.2.2.1. Disease Description
    • 14.2.2.2. Epidemiology
    • 14.2.2.3. Current Treatment Options
    • 14.2.2.4. Microbiome Therapeutics for Lactose Intolerance
  • 14.2.3. Nonalcoholic Steatohepatitis (NASH)
    • 14.2.3.1. Disease Description
    • 14.2.3.2. Epidemiology
    • 14.2.3.3. Current Treatment Options
    • 14.2.3.4. Microbiome Therapeutics for NASH
  • 14.2.4. Primary Hyperoxaluria
    • 14.2.4.1. Disease Description
    • 14.2.4.2. Epidemiology
    • 14.2.4.3. Current Treatment Options
    • 14.2.4.4. Microbiome Therapeutics for Primary Hyperoxaluria
  • 14.2.5. Obesity
    • 14.2.5.1. Disease Description
    • 14.2.5.2. Epidemiology
    • 14.2.5.3. Current Treatment Options
    • 14.2.5.4. Side Effects of Current Treatment Options
    • 14.2.5.5. Microbiome Therapeutics for Obesity
• 14.3. Digestive and Gastrointestinal Disorders
  • 14.3.1. Crohn's Disease
    • 14.3.1.1. Disease Description
    • 14.3.1.2. Epidemiology
    • 14.3.1.3. Current Treatment Options
    • 14.3.1.4. Side Effects of Current Treatment Options
    • 14.3.1.5. Microbiome Therapeutics for Crohn's Disease
  • 14.3.2. Irritable Bowel Syndrome (IBS)
    • 14.3.2.1. Disease Description
    • 14.3.2.2. Epidemiology
    • 14.3.2.3. Current Treatment Options
    • 14.3.2.4. Microbiome Therapeutics for IBS
  • 14.3.3. Ulcerative Colitis
    • 14.3.3.1. Disease Description
    • 14.3.3.2. Epidemiology
    • 14.3.3.3. Current Treatment Options
    • 14.3.3.4. Side Effects of Current Treatment Options
    • 14.3.3.5. Microbiome Therapeutics for Ulcerative Colitis
• 14.4. Oncological Indications
  • 14.4.1. Colorectal Cancer
    • 14.4.1.1. Disease Description
    • 14.4.1.2. Epidemiology
    • 14.4.1.3. Current Treatment Options
    • 14.4.1.4. Side Effects of Current Treatments
    • 14.4.1.5. Microbiome Therapeutics for Colorectal Cancer
  • 14.4.2. Lung Cancer
    • 14.4.2.1. Disease Description
    • 14.4.2.2. Epidemiology
    • 14.4.2.3. Current Treatment Options
    • 14.4.2.4. Side Effects of Current Treatment Options
    • 14.4.2.5. Microbiome Therapeutics for Lung Cancer
• 14.5. Dermatological Disorders
  • 14.5.1. Acne Vulgaris
    • 14.5.1.1. Disease Description
    • 14.5.1.2. Epidemiology
    • 14.5.1.3. Current Treatment Options
    • 14.5.1.4. Side Effects of Current Treatment Options
    • 14.5.1.5. Microbiome Therapeutics for Acne Vulgaris
• 14.6. Infectious Diseases
  • 14.6.1. Clostridium Difficile Infections (CDIs)
    • 14.6.1.1. Disease Description
    • 14.6.1.2. Epidemiology
    • 14.6.1.3. Disease Diagnosis
    • 14.6.1.4. Current Treatment Options
    • 14.6.1.5. Side Effects of Current Treatment Options
    • 14.6.1.6. Microbiome Therapeutics for CDI
  • 14.6.2. Bacterial Vaginosis
    • 14.6.2.1. Disease Description
    • 14.6.2.2. Epidemiology
    • 14.6.2.3. Current Treatment Options
    • 14.6.2.4. Side Effects of Current Treatment Options
    • 14.6.2.5. Microbiome Therapeutics for Bacterial Vaginosis

15. PARTNERSHIPS AND COLLABORATIONS

• 15.1. Chapter Overview
• 15.2. Partnership Models
• 15.3. Human Microbiome: List of Partnerships and Collaborations
• 15.4. Analysis by Year of Partnership
• 15.5. Analysis by Type of Partnership
• 15.6. Analysis by Year and Type of Partnership
• 15.7. Analysis by Type of Product
• 15.8. Analysis by Target Indication
• 15.9. Analysis by Therapeutic Area
• 15.10. Analysis by Type of Company
• 15.11. Analysis by Type of Partner
• 15.12. Most Active Players: Analysis by Number of Partnerships
• 15.13. Intercontinental and Intracontinental Agreements

16. FUNDING AND INVESTMENT ANALYSIS

• 16.1. Chapter Overview
• 16.2. Types of Funding
• 16.3. Microbiome Therapeutics and Diagnostics: List of Funding and Investments
  • 16.3.1. Analysis by Year of Investment
  • 16.3.2. Analysis by Amount Invested
  • 16.3.3. Analysis by Type of Funding
  • 16.3.4. Analysis by Type of Company
  • 16.3.5. Analysis by Purpose of Funding
  • 16.3.6. Analysis by Type of Product
  • 16.3.7. Analysis by Target Indication
  • 16.3.8. Analysis by Therapeutic Area
  • 16.3.9. Analysis by Geography
  • 16.3.10. Most Active Players: Analysis by Number of Instances
  • 16.3.11. Most Active Players: Analysis by Amount Invested
  • 16.3.12. Most Active Investors: Analysis by Number of Instances
  • 16.3.13. Funding and Investment Summary

17. CASE STUDY: CONTRACT SERVICES FOR MICROBIOME THERAPEUTICS AND LIVE BIOTHERAPEUTICS

• 17.1. Chapter Overview
• 17.2. Manufacturing Microbiome Therapeutics
  • 17.2.1. Key Steps Involved
  • 17.2.2. Associated Challenges
  • 17.2.3. Growing Demand for Contract Manufacturing Services
  • 17.2.4. Contract Manufacturing Organizations (CMOs)
    • 17.2.4.1. Introduction to Contract Manufacturing
  • 17.2.5. Microbiome Therapeutics: List of Contract Manufacturing Providers
    • 17.2.5.1. Analysis by Year of Establishment
    • 17.2.5.2. Analysis by Company Size
    • 17.2.5.3. Analysis by Location of Headquarters
    • 17.2.5.4. Analysis by Scale of Operation
    • 17.2.5.5. Analysis by Type of Product Manufactured
    • 17.2.5.6. Analysis by Type of Formulation
    • 17.2.5.7. Analysis by Scale of Operation and Type of Formulation
• 17.3. Key Considerations for Selecting a CMO / CRO Partner

18. BIG DATA AND MICROBIOME THERAPEUTICS

• 18.1. Chapter Overview
• 18.2. Introduction to Big Data
• 18.3. Internet of Things (IoT)
• 18.4. Growing Interest in Big Data: Google Trends Analysis
• 18.5. Key Application Areas
• 18.6. Big Data in Microbiome Research
  • 18.6.1. Microbiome Data and Personalized Medicine
  • 18.6.2. Microbiome-related Data Management Challenges
  • 18.6.3. National Microbiome Data Center
• 18.7. Big Data Services for Microbiome Research: List of Companies
• 18.8. Big Data Services for Microbiome Research: Profiles of Key Players
  • 18.8.1. Human Longevity
    • 18.8.1.1. Company Overview
    • 18.8.1.2. Technology and Service Portfolio
    • 18.8.1.3. Recent Developments and Future Outlook
  • 18.8.2. Resilient Biotics
    • 18.8.2.1. Company Overview
    • 18.8.2.2. Technology and Service Portfolio
    • 18.8.2.3. Recent Developments and Future Outlook
  • 18.8.3. Resphera Biosciences
    • 18.8.3.1. Company Overview
    • 18.8.3.2. Technology and Service Portfolio
    • 18.8.3.3. Recent Developments and Future Outlook

19. MICROBIOME THERAPEUTICS: MARKET FORECAST AND OPPORTUNITY ANALYSIS

• 19.1. Chapter Overview
• 19.2. Key Assumptions
• 19.3. Forecast Methodology
• 19.4. Global Microbiome Therapeutics Market, Till 2035
  • 19.4.1. Microbiome Therapeutics Market: Distribution by Type of Product Till 2035
    • 19.4.1.1. Microbiome Therapeutics Market for Probiotic Drugs, Till 2035
    • 19.4.1.2. Microbiome Therapeutics Market for Other Drugs, Till 2035
  • 19.4.2. Microbiome Therapeutics Market: Distribution by Target Disease Indication, Till 2035
    • 19.4.2.1. Microbiome Therapeutics Market for Graft Versus Host Disease, Till 2035
    • 19.4.2.2. Microbiome Therapeutics Market for Necrotizing Enterocolitis, Till 2035
    • 19.4.2.3. Microbiome Therapeutics Market for Primary Hyperoxaluria, Till 2035
    • 19.4.2.4. Microbiome Therapeutics Market for Recurrent C. difficile Infection, Till 2035
  • 19.4.3. Microbiome Therapeutics Market: Distribution by Therapeutic Area, Till 2035
    • 19.4.3.1. Microbiome Therapeutics Market for Digestive and Gastrointestinal Disorders, Till 2035
    • 19.4.3.2. Microbiome Therapeutics Market for Infectious Diseases, Till 2035
    • 19.4.3.3. Microbiome Therapeutics Market for Rare Disorders, Till 2035
  • 19.4.4. Microbiome Therapeutics Market: Route of Administration, Till 2035
    • 19.4.4.1. Microbiome Therapeutics Market for Oral Therapeutics, Till 2035
    • 19.4.4.2. Microbiome Therapeutics Market for Rectal Therapeutics, Till 2035
  • 19.4.5. Microbiome Therapeutics Market: Distribution by Type of Formulation, Till 2035
    • 19.4.5.1. Microbiome Therapeutics Market for Capsules, Till 2035
    • 19.4.5.2. Microbiome Therapeutics Market for Suspensions, Till 2035
    • 19.4.5.3. Microbiome Therapeutics Market for Enemas, Till 2035
  • 19.4.6. Microbiome Therapeutics Market: Distribution by Key Geographical Regions, Till 2035
    • 19.4.6.1. Microbiome Therapeutics Market in North America, Till 2035
    • 19.4.6.2. Microbiome Therapeutics Market in Europe, Till 2035
    • 19.4.6.3. Microbiome Therapeutics Market in Asia-Pacific and Rest of the World, Till 2035
  • 19.4.7. Microbiome Therapeutics Market: Distribution by Leading Drug Developers, Till 2035
  • 19.4.8. Microbiome Therapeutics Market: Distribution by Leading Therapeutic Products, Till 2035
    • 19.4.8.1. SER-109 (Seres Therapeutics)
    • 19.4.8.2. RBX2660 (ReBiotix)
    • 19.4.8.3. CP101 (Finch Therapeutics)
    • 19.4.8.4. IBP-9414 (Infant bacterial Therapeutics)
    • 19.4.8.5. Oxabact (OxThera)
    • 19.4.8.6. MaaT013 (MaaT Pharma)

20. MICROBIOME DIAGNOSTICS: MARKET FORECAST AND OPPORTUNITY ANALYSIS

• 20.1. Chapter Overview
• 20.2. Scope and Limitations
• 20.3. Forecast Methodology
• 20.4. Global Human Microbiome Diagnostic Test Market, Till 2035
  • 20.4.1. Human Microbiome Diagnostic Tests Market by Target Indication
    • 20.4.1.1. Human Microbiome Diagnostic Tests Market for Inflammatory Bowel Syndrome, Till 2035
    • 20.4.1.2. Human Microbiome Diagnostic Tests Market for Irritable Bowel Disease, Till 2035
    • 20.4.1.3. Human Microbiome Diagnostic Tests Market for Colorectal Cancer, Till 2035
    • 20.4.1.4. Human Microbiome Diagnostic Tests Market for Diabetes Mellitus, Till 2035
  • 20.4.2. Human Microbiome Diagnostic Tests Market: Distribution by Therapeutic Area
    • 20.4.2.1. Human Microbiome Diagnostic Tests Market for Digestive and Gastrointestinal Disorders, Till 2035
    • 20.4.2.2. Human Microbiome Diagnostic Tests Market for Oncological Disorders, Till 2035
    • 20.4.2.3. Human Microbiome Diagnostic Tests Market for Metabolic Disorders, Till 2035
  • 20.4.3. Human Microbiome Diagnostic Tests Market: Distribution by Key Geographical Regions
    • 20.4.3.1. Human Microbiome Diagnostic Tests Market in North America, Till 2035
    • 20.4.3.2. Human Microbiome Diagnostic Tests Market in Europe, Till 2035
    • 20.4.3.3. Human Microbiome Diagnostic Tests Market in Asia Pacific, Till 2035

21. FECAL MICROBIOTA THERAPIES: MARKET FORECAST AND OPPORTUNITY ANALYSIS

• 21.1. Chapter Overview
• 21.2. Forecast Methodology and Key Assumptions
• 21.3. Global Fecal Microbiota Therapies Market, Till 2035
  • 21.3.1. Global Fecal Microbiota Therapies Market, Till 2035 (By Value)
  • 21.3.2. Global Fecal Microbiota Therapies Market, Till 2035 (By Value)
  • 21.3.3. Overall FMT Market, Till 2035 (By Volume)
• 21.4. Overall Microbiome Market by Product Offerings, Till 2035

22. CASE STUDY: MICROBIOME-BASED PRODUCTS IN NON-PHARMACEUTICAL INDUSTRIES

• 22.1. Chapter Overview
• 22.2. List of Microbiome Products in Non-Pharmaceutical Industry
  • 22.2.1. Applications of Microbiome Based Products in Cosmetics and Food Industry
• 22.3. Applications of Microbiome Based Products in Agriculture Industry
• 22.4. Future Perspectives

23. CONCLUDING REMARKS

24. EXECUTIVE INSIGHTS

• 24.1. Chapter Overview
• 24.2. Company A
  • 24.2.1. Company / Organization Snapshot
  • 24.2.2. Interview Transcript: Senior Manager, Corporate Development
• 24.3. Company B
  • 24.3.1. Company / Organization Snapshot
  • 24.3.2. Interview Transcript: Co-founder and Chairman
• 24.4. Company C
  • 24.4.1. Company / Organization Snapshot
  • 24.4.2. Interview Transcript: Chief Executive Officer
• 24.5. Company D
  • 24.5.1. Company / Organization Snapshot
  • 24.5.2. Interview Transcript: Senior Scientist
• 24.6. Company E
  • 24.6.1. Company / Organization Snapshot
  • 24.6.2. Interview Transcript: Associate General Manager
• 24.7. Company F
  • 24.7.1. Company / Organization Snapshot
  • 24.7.2. Interview Transcript: Ex-Vice President, Business Development
• 24.8. Company G
  • 24.8.1. Company / Organization Snapshot
  • 24.8.2. Interview Transcript: Chief Business Officer
• 24.9. Company H
  • 24.9.1. Company / Organization Snapshot
  • 24.9.2. Interview Transcript: Ex-Vice President, Sales and Business Development
• 24.10. Company I
  • 24.10.1. Company / Organization Snapshot
  • 24.10.2. Interview Transcript: Co-founder and Chief Executive Officer
• 24.11. Company J
  • 24.11.1. Company / Organization Snapshot
  • 24.11.2. Interview Transcript: Co-founder and Chief Executive Officer
• 24.12. Company K
  • 24.12.1. Company / Organization Snapshot
  • 24.12.2. Interview Transcripts: Co-founder and Chief Executive Officer
• 24.13. Company L
  • 24.13.1. Company / Organization Snapshot
  • 24.13.2. Interview Transcripts: Ex-Co-founder and Vice President of Innovation
• 24.14. Company M
  • 24.14.1. Company / Organization Snapshot
  • 24.14.2. Interview Transcript: Vice President, Business Development and Marketing
• 24.15. Company N
  • 24.15.1. Company / Organization Snapshot
  • 24.15.2. Interview Transcript: Ex-Vice President, Operations
• 24.16. Company O
  • 24.16.1. Company / Organization Snapshot
  • 24.16.2. Interview Transcript: President and Chief Executive Officer
• 24.17. Company P
  • 24.17.1. Company / Organization Snapshot
  • 24.17.2. Interview Transcript: Ex-Chief Scientific Officer and Vice President
• 24.18. Company Q
  • 24.18.1. Company / Organization Snapshot
  • 24.18.2. Interview Transcript: Chief Strategy Officer

25. APPENDIX I: TABULATED DATA

26. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS